<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0004808'>Acute myeloid leukemia</z:hpo> preceded by a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) is generally regarded as a high-risk type of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, where remissions are rare and of short duration </plain></SENT>
<SENT sid="1" pm="."><plain>Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) is suggested to increase the sensitivity of leukemic cells to cycle-specific drugs </plain></SENT>
<SENT sid="2" pm="."><plain>In this study 14 MDS-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients were given rhGM-CSF together with standard induction chemotherapy (TAD) </plain></SENT>
<SENT sid="3" pm="."><plain>rhGM-CSF was started 48 h prior to chemotherapy and given for up to 3 weeks </plain></SENT>
<SENT sid="4" pm="."><plain>The results showed eight (58%) complete and two (14%) partial remissions, while another two (14%) patients had minor responses </plain></SENT>
<SENT sid="5" pm="."><plain>One patient relapsed after 1 year, and then responded a second time </plain></SENT>
<SENT sid="6" pm="."><plain>rhGM-CSF had to be stopped owing to local allergic reactions in two patients, both non-responders, but was otherwise well tolerated </plain></SENT>
<SENT sid="7" pm="."><plain>Compared with our historical group of controls we found significantly higher remission rates, fewer early <z:hpo ids='HP_0011420'>deaths</z:hpo>, fewer <z:hpo ids='HP_0001945'>fever</z:hpo> days, and fewer days with both <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> among the patients treated with rhGM-CSF and TAD </plain></SENT>
<SENT sid="8" pm="."><plain>The estimated median over-<z:hpo ids='HP_0000001'>all</z:hpo> survival was 332 days </plain></SENT>
<SENT sid="9" pm="."><plain>The severity of initial myelodysplastic changes did not correlate to the outcome of therapy but the degree of peripheral blood <z:mpath ids='MPATH_589'>dysplasia</z:mpath> decreased among responding patients </plain></SENT>
<SENT sid="10" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients in this pilot study did respond better, and with minimal toxicity, when standard induction chemotherapy was given in combination with rhGM-CSF </plain></SENT>
</text></document>